6.15

5.82% -0.38

After Hours: 6.10 -0.05 -0.81%

Nuvectis Pharma Inc (NVCT)

Overview News Price History Financials Discussions Forecast

Nuvectis Pharma Inc stock is currently priced at $6.15, with a 24-hour trading volume of 109.72K. It has seen a -5.82% decreased in the last 24 hours and a -9.02% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $6.51 pivot point. If it approaches the $6.07 support level, significant changes may occur.

Previous Close:

$6.53

Open:

$6.55

24h Volume:

109.72K

Market Cap:

$112.89M

Revenue:

Net Income/Loss:

$-22.26M

P/E Ratio:

-3.9677

EPS:

-1.55

Net Cash Flow:

$-15.95M

1W Performance:

-3.91%

1M Performance:

-9.02%

6M Performance:

-25.00%

1Y Performance:

-63.82%

1D Range:

$6.07

$6.60

52W Range:

$5.92

$18.65

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Name

Nuvectis Pharma Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

201-614-3150

Address

1 Bridge Plaza, Suite 275, Fort Lee

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

NVCT's Discussions on Twitter

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-13-22	Initiated	Ladenburg Thalmann	Buy

Nuvectis Pharma Inc Stock (NVCT) Latest News

Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy (NASDAQ:NVCT) - Seeking Alpha

Seeking Alpha

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire

GlobeNewswire

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

GlobeNewswire Inc.

Nuvectis Pharma CEO buys shares worth over $13k - Investing.com Nigeria

Investing.com Nigeria

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires $13,075.60 in Stock - MarketBeat

MarketBeat

Nuvectis Pharma CEO buys shares worth over $13k By Investing.com - Investing.com

Investing.com

Nuvectis Pharma Inc Stock (NVCT) Financials Data

Nuvectis Pharma Inc (NVCT) Net Income 2024

NVCT net income (TTM) was -$22.26 million for the quarter ending December 31, 2023, a -16.64% decrease year-over-year.

Nuvectis Pharma Inc (NVCT) Cash Flow 2024

NVCT recorded a free cash flow (TTM) of -$15.95 million for the quarter ending December 31, 2023, a -17.66% decrease year-over-year.

Nuvectis Pharma Inc (NVCT) Earnings per Share 2024

NVCT earnings per share (TTM) was -$1.43 for the quarter ending December 31, 2023, a +4.67% growth year-over-year.

Nuvectis Pharma Inc Stock (NVCT) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
BENTSUR RON	Chairman & CEO	May 10 '24	Buy	6.40	2,000	12,800	3,244,484
Shemesh Shay	Chief Dev. & Ops. Officer	May 10 '24	Buy	6.32	1,113	7,034	1,493,068
Poradosu Enrique	Chief Science & Business Off	May 10 '24	Buy	6.29	500	3,145	1,504,319
BENTSUR RON	Chairman & CEO	Mar 18 '24	Buy	10.29	5,000	51,450	3,242,484
BENTSUR RON	Chairman & CEO	Oct 10 '23	Buy	11.08	640	7,091	3,237,484
BENTSUR RON	Chairman & CEO	Oct 09 '23	Buy	11.19	830	9,288	3,236,844
BENTSUR RON	Chairman & CEO	Oct 06 '23	Buy	11.27	250	2,818	3,236,014
BENTSUR RON	Chairman & CEO	Oct 05 '23	Buy	11.09	1,400	15,526	3,235,764
BENTSUR RON	Chairman & CEO	Oct 04 '23	Buy	10.95	1,820	19,929	3,234,364
BENTSUR RON	Chairman & CEO	Aug 16 '23	Buy	15.15	115	1,742	3,232,544

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.